尊龙凯时·(中国区)人生就是搏!

|
EN
|
EN
EN

  • 业务咨询

    中国：

    Email: marketing@scjnnt.com

    业务咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jul 05,2023
苯并咪唑衍生物XY123是一种口服有效的选择性RORγ反向激动剂。在本研究中，所有肝微粒体测定均通过尊龙凯时 - 人生就是搏!进行
Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. XY123 potently inhibits the RORγ transcription activity with an IC50 value of 64 nM. XY123 demonstrates good metabolic stability and a pharmacokinetics property with reasonable oral bioavailability (32.41%) and moderate half-life (4.98 h). All liver microsome assays were performed by Medicilon.
查看更多
苯并咪唑衍生物XY123是一种口服有效的选择性RORγ反向激动剂。在本研究中，所有肝微粒体测定均通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
zapERtrap：光调节的内质网释放系统揭示了意想不到的神经元运输途径，Zapalog的合成通过尊龙凯时 - 人生就是搏!进行
zapERtrap opens the door to previously unapproachable questions concerning how proteins are processed, trafficked, and secreted in space and time in complex cellular environments. zapERtrap relies on a small-molecule protein dimerizer zapalog, which consists of the antibiotic trimethoprim tethered to a synthetic ligand of FK506-binding protein through a photocleavable linker. Synthesis of zapalog was performed by Medicilon.
查看更多
zapERtrap：光调节的内质网释放系统揭示了意想不到的神经元运输途径，Zapalog的合成通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
端锚聚合酶1/2影响WNT/β-连环蛋白和Hippo信号通路，这些信号通路涉及包括肿瘤在内的多种疾病
Tankyrase 1 and 2 (TNKS1/2) impact the WNT/β-catenin and Hippo signaling pathways that are involved in numerous human disease conditions including cancer. OM-153 shows picomolar IC50 inhibition in a cellular (HEK293) WNT/β-catenin signaling reporter assay, no off-target liabilities, overall favorable ADME properties, and an improved pharmacokinetic profile in mice. The pharmacokinetic analyses in mice were performed according to the standard protocols of Medicilon.
查看更多
端锚聚合酶1/2影响WNT/β-连环蛋白和Hippo信号通路，这些信号通路涉及包括肿瘤在内的多种疾病
Jul 05,2023
设计合成和评估用于治疗前列腺癌的CBP溴结构域抑制剂。PK评估、肝微粒体稳定性测定和Caco-2渗透性测定通过尊龙凯时 - 人生就是搏!进行
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer mortalities in men. CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Researchers designed 1-(Indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. Pharmacokinetic properties evaluation were analyzed by Medicilon. Liver microsomal stability assay were performed at Medicilon. Caco-2 permeability assay was analyzed by Medicilon.
查看更多
设计合成和评估用于治疗前列腺癌的CBP溴结构域抑制剂。PK评估、肝微粒体稳定性测定和Caco-2渗透性测定通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
研究人员使用RZ-2994来表征抑制SHMT1/2在T细胞急性淋巴细胞白血病 (T-ALL) 中的作用，RZ-2994通过尊龙凯时 - 人生就是搏!定制合成
​Despite progress in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Researchers used SHMT1/2 inhibitor RZ-2994 to characterize the effect of inhibiting SHMT1/2 in T-ALL. Loss of both SHMT1/2 is necessary for impaired growth and cell cycle arrest, with suppression of SHMT1/2 inhibiting leukemia progression. RZ-2994 also decreases leukemia burden in vivo. RZ-2994 was obtained from Medicilon. Medicilon offers a full range of chemical services covering all phases of your project. Customers can work with us either through FFS or FTE.
查看更多
研究人员使用RZ-2994来表征抑制SHMT1/2在T细胞急性淋巴细胞白血病 (T-ALL) 中的作用，RZ-2994通过尊龙凯时 - 人生就是搏!定制合成
Jul 05,2023
研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂，抗肿瘤药效研究通过尊龙凯时 - 人生就是搏!进行
Cell division cycle 7 (CDC7) plays important roles in DNA replication. Researchers developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent. The antitumor efficacy studies in PDX models were performed at Medicilon. Medicilon has established a complete evaluation system for preclinical anti-tumor efficacy, and has more than 200 different types of tumor efficacy models.
查看更多
研究人员开发了一种高特异性的CDC7抑制剂TAK-931作为临床肿瘤治疗剂，抗肿瘤药效研究通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
研究新型多靶点抗高血压药MT-1207的药理学特性，评价MT-1207的结合抑制活性通过尊龙凯时 - 人生就是搏!进行
Hypertension is a serious public health problem worldwide. MT-1207 is a chemical entity that has entered into clinical trial as antihypertensive agent. MT-1207 potently inhibits adrenergic α1A, α1B, α1D, and 5-HT2A receptors with Ki<1 nM in a panel of enzyme activity or radioligand binding assays. The binding inhibition activities of MT-1207 were evaluated by Medicilon.
查看更多
研究新型多靶点抗高血压药MT-1207的药理学特性，评价MT-1207的结合抑制活性通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
设计、合成和评估具有体内抗炎活性的RIPK1抑制剂，PK研究通过尊龙凯时 - 人生就是搏!进行
RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, researchers report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. The pharmacokinetic parameters were determined at Medicilon using male SD rats (3 rats per group, 4 groups).
查看更多
设计、合成和评估具有体内抗炎活性的RIPK1抑制剂，PK研究通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
合成一类新型选择性TNIK抑制剂并评估其抗结直肠癌作用，PK研究通过尊龙凯时 - 人生就是搏!进行
The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer. SAR analysis leads to the identification of a number of potent TNIK inhibitors with Compound 21k being the most active one. Preliminary assessment for the pharmacokinetic properties of 21k was carried out through services provided by Medicilon.
查看更多
合成一类新型选择性TNIK抑制剂并评估其抗结直肠癌作用，PK研究通过尊龙凯时 - 人生就是搏!进行
Jul 05,2023
用于治疗非酒精性脂肪性肝炎的PPARα/δ 双重激动剂的设计合成和生物学评价，PK研究、hERG研究和Ames试验通过尊龙凯时 - 人生就是搏!进行
Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPARα/δ dual agonists. The pharmacokinetic studies were conducted by Medicilon. The hERG channel inhibition studies were conducted by Medicilon. The Ames tests were conducted by Medicilon.
查看更多
用于治疗非酒精性脂肪性肝炎的PPARα/δ 双重激动剂的设计合成和生物学评价，PK研究、hERG研究和Ames试验通过尊龙凯时 - 人生就是搏!进行
×
搜索验证
点击切换
友情链接: